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Epigenetic modifications, such as histone post-translational modifications, DNA meth-
ylation, and alteration of gene expression by non-coding RNAs, including microRNAs 
(miRNAs) and long non-coding RNAs (lncRNAs), are heritable changes that are indepen-
dent from the genomic DNA sequence. These regulate gene activities and, therefore, 
cellular functions. Epigenetic modifications act in concert with transcription factors and 
play critical roles in B cell development and differentiation, thereby modulating antibody 
responses to foreign- and self-antigens. Upon antigen encounter by mature B cells in 
the periphery, alterations of these lymphocytes epigenetic landscape are induced by 
the same stimuli that drive the antibody response. Such alterations instruct B cells to 
undergo immunoglobulin (Ig) class switch DNA recombination (CSR) and somatic hyper-
mutation (SHM), as well as differentiation to memory B cells or long-lived plasma cells 
for the immune memory. Inducible histone modifications, together with DNA methylation 
and miRNAs modulate the transcriptome, particularly the expression of activation-in-
duced cytidine deaminase, which is essential for CSR and SHM, and factors central to 
plasma cell differentiation, such as B lymphocyte-induced maturation protein-1. These 
inducible B cell-intrinsic epigenetic marks guide the maturation of antibody responses. 
Combinatorial histone modifications also function as histone codes to target CSR and, 
possibly, SHM machinery to the Ig loci by recruiting specific adaptors that can stabilize 
CSR/SHM factors. In addition, lncRNAs, such as recently reported lncRNA-CSR and an 
lncRNA generated through transcription of the S region that form G-quadruplex struc-
tures, are also important for CSR targeting. Epigenetic dysregulation in B cells, including 
the aberrant expression of non-coding RNAs and alterations of histone modifications and 
DNA methylation, can result in aberrant antibody responses to foreign antigens, such as 
those on microbial pathogens, and generation of pathogenic autoantibodies, IgE in aller-
gic reactions, as well as B cell neoplasia. Epigenetic marks would be attractive targets 
for new therapeutics for autoimmune and allergic diseases, and B cell malignancies.
Keywords: AiD, B cell, Blimp-1, class switch DNA recombination, epigenetics, histone post-translational 
modification, memory B cell, microRNA, plasma cell differentiation, somatic hypermutation
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iNTRODUCTiON
Epigenetic changes brought about by genetic susceptibility and/
or environmental exposure can modulate gene expression and 
alter cellular functions without altering genomic sequences (1). 
Epigenetic modifications and factors, such as DNA methylation, 
histone post-translational modifications and non-coding RNAs, 
such as microRNAs (miRNAs) and long non-coding RNAs 
(lncRNAs), comprise the epigenome and interact with genetic 
programs to regulate immune responses. Immunoglobulin (Ig) 
class switch DNA recombination (CSR) and somatic hypermuta-
tion (SHM) are critical for the production of protective antibod-
ies against microbial pathogens, IgE in allergic responses, as 
well as pathogenic autoantibodies in autoimmune diseases. CSR 
recombines S region DNA located upstream of constant heavy-
chain (CH) region exons, thereby encoding new Ig CH regions that 
endow antibodies new biological effector functions (2). SHM 
introduces mostly point mutations in variable regions of Ig heavy 
and light chains, thereby providing the structural substrate for 
antigen-mediated selection of B cell mutants with higher affinity 
B cell receptors (BCRs) (3–5). CSR and SHM occur mainly in 
germinal center and require activation-induced cytidine deami-
nase (AID, encoded by AICDA in humans and Aicda in mice), 
which is expressed in a differentiation stage-specific fashion in 
B cells (2–4). Class switched and hypermutated B cells further 
differentiate into long-lived memory B cells, which can react 
quickly to a recurrent antigenic challenge, or antibody-secreting 
plasma cells in a fashion critically dependent on B lymphocyte-
induced maturation protein 1 (Blimp-1, encoded by PRDM1 in 
humans and Prdm1 in mice) (6, 7). Epigenetic modifications and 
factors influence gene expression and modulate critical B cell 
processes, such as CSR, SHM, and differentiation to memory B 
cells or plasma cells, thereby informing the antibody response (4, 
8–10). Epigenetic dysregulation can result in aberrant antibody 
responses to exogenous antigens or self-antigens, such as chro-
matin, histones, and double-strand DNA in lupus.
B cell development and differentiation occur in two sequential 
stages. The initial, antigen-independent stage occurs in the bone 
marrow and involves recombination activating gene (RAG)1/
RAG2-dependent V-(D)-J DNA rearrangement, which produces 
clonally unique Ig variable regions that specifically bind antigen. 
This stage generates mature, immunocompetent B cells that can 
bind to a unique antigen. The B cells move into the periphery 
and complete further, antigen-independent maturation into 
immunocompetent naïve mature B cells. In the periphery lym-
phoid organs, B cell undergoes the antigen-dependent stage of 
development or differentiation, upon activation by antigen bind-
ing and co-stimulation (5). In this stage, resting naïve mature B 
cells are induced to undergo cell proliferation, CSR, as well as 
SHM-mediated antibody affinity maturation, and differentiate 
into memory B cells, or short- or long-lived antibody-secreting 
plasma cells (6, 7). Multiple epigenetic changes are associated 
with each B cell development and differentiation stage. Resting, 
naïve B cells undergo VHDJH-Cμ transcription, which initiates 
at the VH promoter and runs through the intronic Sμ region 
and Cμ/Cδ exon clusters. This encodes the surface BCR, which 
comprises Igμ and Igδ heavy chain genes. These resting B cells 
display low levels of overall histone acetylation and genome-
wide DNA hypermethylation, therefore most regions within the 
Ig heavy chain (IgH) locus are in a closed chromatin state (11), 
enriched in repressive histone post-translational modifications 
(e.g., H3K9me3 and H3K27me3) but lacking of activated histone 
modifications (12, 13). In B cells, epigenetic marks, such as DNA 
methylation, histone modifications, and miRNAs, are induced by 
the same stimuli that drive the antibody response, and modulate 
the transcriptome, especially the expression of AID, which is 
essential for SHM and CSR, and factors critical for plasma cell 
differentiation, such as Blimp-1 (4). By functioning as histone 
codes, combinatorial histone modifications also play a role in the 
targeting of the CSR and, possibly, SHM machinery to the Ig loci 
through recruiting specific scaffold proteins that stabilize CSR/
SHM factors (8). These inducible B cell-intrinsic epigenetic marks 
control transcription programs that distinguish individual stages 
of B cell differentiation and underpin the molecular changes that 
are necessary for antibody response.
In this review, we provide a conceptual framework to under-
stand how epigenetic modifications/factors modulate CSR and 
SHM, and the generation of plasma cells and memory B cells, 
with focus on AID-dependent peripheral B cell differentiation 
into memory B cells and long-lived plasma cells (but not dif-
ferentiation of naïve B cells to short-lived plasma cells). We also 
highlight our current understanding of epigenetic modulations 
of CSR, SHM, and plasma cell differentiation by histone deacety-
lases (HDACs) inhibitors (HDIs). Finally, we summarize recent 
discoveries that indicate the importance of B cell epigenetic 
dysregulation in autoimmunity and B cell neoplasia.
ePiGeNeTiC ReGULATiON OF AiD 
iNDUCTiON
Somatic hypermutation and CSR are initiated by transcription 
through V(D)J and the donor/acceptor S regions that will undergo 
recombination, respectively, and are mediated by AID, a 198 
amino acid protein, which is structurally and functionally similar 
to apolipoprotein B RNA-editing cytidine deaminases (APOBEC 
enzymes) (2, 3). AID shares a conserved catalytic domain with other 
members of the APOBEC family of cytosine or cytidine deaminases 
(3). It deaminates deoxycytidines (dCs) into deoxyuracils (dUs) 
yielding dU:dG mismatches. These mismatches can be repaired 
by an error-prone DNA repair pathway, which introduce somatic 
mutations, or processed by uracil DNA glycosylase (Ung), which is 
recruited to and stabilized on S regions by the scaffold functions of 
14-3-3 adaptors, the translesion DNA synthesis (TLS) polymerase 
Rev1 and replication protein A (RPA), or elements of the mismatch 
repair (MMR) machinery, such as Msh2 and Msh6, which trigger 
DNA repair processes leading to introduction of point mutations 
(SHM) or double-strand DNA breaks (DSBs) (CSR) (2).
As a potent mutator, AID can effectively introduce mutations 
in not only Ig loci but also a variety of non-Ig genes, thereby 
causing genome instability in both B cells and non-B cells, 
including non-lymphoid cells, and contributing to tumorgenesis 
(3). Tight regulation of AID expression and function is necessary 
to maintain genomic stability in both B cells and non-B cells, 
FiGURe 1 | AiD is tightly regulated at the transcriptional, post-transcriptional, and post-translational levels. Four distinct DNA regions (regions I–IV) of the 
AID gene (Aicda) locus possess binding sites for multiple transcription factors to regulate Aicda expression. Region I functions as promoters containing the binding 
sites for HoxC4/Oct and NF-κB/Sp1/Sp3, which can be induced by activating the Aicda promoter. In resting naive and memory B cells, and non-B cells, silencer 
elements in region II bind the repressor proteins E2f and c-Myb to counter the activity of the transcriptional activators. Stimulation of B cells with the primary 
inducing stimuli and cytokines that promote CSR induce activation signals through region IV enhancer in collaboration with the intronic enhancer in region II can 
overcome the effect of the region II silencer. After transcription, the Aicda mRNA can be negatively regulated by miR-155, miR-181b, and miR-361, which 
specifically bind to the conserved target sites on the 3′ UTR of Aicda mRNA. Nuclear AID is either degraded or exported back to the cytoplasm. Only a small 
proportion of AID molecules are targeted onto DNA at Ig or non-Ig loci by its co-factors. AID preferentially deaminates single-strand DNA, which emerges from 
transcription by RNA Pol II and depends on histone modifications in the transcribed locus. AID can be recruited to the open DNA before or during transcription. In 
CSR, AID recruitment to S regions occurs with interaction of RNA Pol II and AID-interacting factors, such as Spt5, Spt6, PTBP2, RNA exosome, lncRNAs, and 
14-3-3 adaptor proteins, which would form a macromolecular complex. AID is enriched and stabilized on the targeted DNA by 14-3-3 adaptor proteins, which 
access the same S regions as the transcription machinery owing to their open chromatin state. These 14-3-3 adaptors are recruited and/or stabilized through 
interactions with 5′-AGCT-3′ repeats and possibly by H3K9acS10ph. The RNA exosome also interacts with AID and allows AID to deaminate both the transcribed 
and the non-transcribed DNA strand in the S regions undergoing transcription. AID deaminate dCs into dUs to yield dU:dG mismatches. Resolution of these lesions 
can lead to different physiological or pathological outcomes.
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and to avoid damages, such as chromosomal translocations, 
resulting from its dysregulation (14–18). This is achieved 
through fine control of transcription, post-transcription and 
post-translation regulation, nuclear/cytoplasmic distribution, 
stability, and activity (3) (Figure 1). AID express at a very low 
level (mostly undetectable) in naïve B cells, it is greatly induced 
in B cells undergoing SHM/CSR, and repressed in memory B 
cells and plasma cells to preserve the specificity, affinity, and 
isotype of antibody and BCR. Aicda transcription is under the 
control of multiple elements, particularly Homeobox protein C4 
(HoxC4) (Figure  1). HoxC4 is a highly conserved helix-loop-
helix homeodomain-containing transcription factor. As we have 
shown, HoxC4 directly binds to the Aicda promoter through an 
evolutionarily conserved 5′-ATTT-3′ site embedded within a 
conserved binding site for POU domain-containing transcrip-
tion factors Oct1 and Oct2 (5′-ATTTGAAT-3′) (19). Sp1/Sp3 
and NF-κB also bind the same promoter core and synergize with 
HoxC4 for Aicda induction (19, 20).
Regulation of AiD expression by DNA 
Modifications and Histone Modifications
The expression of Aicda is modulated by changes of Aicda epigenetic 
status. Suppression of Aicda expression in naïve B cells is medi-
ated by promoter DNA hypermethylation (21). In naive B cells, in 
which AID is not expressed, histone H3 acetylation occurs in the 
Aicda gene at low levels comparable to the overall H3 acetylation 
in the genome and neighboring genes, such as Mfap5, which is not 
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significantly expressed in B cells (22). Upon activation of B cells, 
DNA of the Aicda gene is demethylated and the locus becomes 
enriched in H3K4me3 and H3K9ac/K14ac. B cell activation by LPS 
plus IL-4, which induces Aicda transcription, greatly increases H3 
acetylation at the Aicda locus, particularly in the Aicda regulatory 
regions (22). These epigenetic modifications, together with induc-
tion of nuclear factor NF-κB, homeobox protein HoxC4 and other 
transcription factors, activate Aicda transcription. Transcription 
elongation depends on the H3K36me3 posttranslational modici-
fication, an intragenic mark of gene activation in the Aicda gene 
body, as suggested by AID down-regulation following depletion of 
the H3K36me3 methyltransferase Setd2 (3, 23). Post-CSR/SHM 
down-regulation of Aicda transcription probably results from 
remethylation of the Aicda DNA.
Regulation of AiD expression by miRNA
In addition to DNA methylation of the Aicda promoter and 
histone acetylation of the Aicda locus, selected miRNAs provide 
a more important mechanism of modulation of AID expression. 
miRNAs are small (~21–23  nt), evolutionarily conserved non-
coding RNAs derived from much larger primary transcripts 
encoded by their “host genes.” miRNAs bind to complementary 
sequences within the 3′ untranslated region (3′ UTR) of their 
target mRNAs and negatively regulate protein expression at the 
post-transcriptional level. miRNA can recognize its target mRNA 
through the short (as few as 6–8 nt) “seed sequence” at the 5′ end 
of the miRNA. miRNA repress gene expression by accelerating 
mRNA degradation and inhibiting mRNA translation. A given 
miRNA can potentially target different mRNAs, and a given 
mRNA can be targeted by multiple miRNAs. The mammalian 
genome encodes hundreds of miRNAs that collectively impact 
the expression of about one-third of all genes. miRNAs are 
transcribed from intergenic genomic DNA by RNA polymerase 
(Pol) II or Pol III as primary transcripts (pri-miRNAs) that are 
then cleaved by the nuclear ribonuclease Drosha to generate an 
about 70 bp long characteristic stem-loop structure, known as a 
pre-miRNA, and exported to the cytoplasm (24). The pre-miRNA 
is further processed by cytoplasmic enzyme Dicer into mature 
miRNA (24), which forms complexes with ribonucleoproteins 
(RNPs) and expresses regulatory effects (25, 26).
microRNAs control various biological processes by fine-tuning 
gene expression at the post-transcriptional level. They can modu-
late a wide range of physiological and pathological processes by 
regulating cellular function at every aspect, from proliferation 
and apoptosis to differentiation. miRNAs are present in all human 
and mouse cells, in which they each modulate the expression of 
a few to hundreds of target genes. miRNAs likely play important 
roles in B cell development and peripheral differentiation, as well 
as T cell stage-specific differentiation and autoimmunity. Naïve 
B cells, germinal center B cells, memory B cells, and plasma cells 
show distinct miRNA expression profiles (27, 28). Deletion of 
Dicer, which is critical for miRNA maturation, in activated B 
cells resulted in defective generation of germinal center B cells, 
memory B cells, and plasma cells (29). Indeed, Dicer-deficient 
B cells showed impaired biogenesis of many miRNAs, includ-
ing miR-155 and miR-125b, which regulate expression of genes 
that modulate B cell germinal center reaction and plasma cell 
differentiation (30, 31). A single miRNA, such as miR-155, can 
target multiple genes, including Myd88, Pu.1, and Aicda, and 
regulate sequential stages of B cell differentiation (30, 32–34). 
By contrast, multiple miRNAs, such as miR-15a and miR-16, can 
cooperatively repress one critical gene in germinal center B cells, 
Bcl2 (27).
miR-155, miR-181b, and miR-361 modulate AID expression by 
binding to the evolutionarily conserved target sites in the 3′ UTR 
of AICDA/Aicda mRNA, thereby reducing both AICDA/Aicda 
mRNA and AID protein levels (33–37). These miRNAs could sup-
press AID expression in naïve B cells and in B cells that completed 
SHM/CSR. miR-155 is the most abundant miRNA that has been 
shown to silence AID expression. miR-155 is processed from an 
RNA sequence encoded by miR-155 host gene (miR155HG). This 
was originally identified as a gene transcriptionally activated by 
promoter insertion at a common retroviral integration site in B-cell 
lymphomas (Bic, B-cell integration cluster). Bic RNA is a spliced 
and polyadenylated but non-protein-coding RNA that accumu-
lates in lymphoma cells (32) and is induced along with AID in B 
cells activated by CSR-inducing stimuli (33, 34). The sequences of 
pre-miRNA-155 and mature miR-155 are highly conserved across 
more than 22 different organisms, including mammals, amphib-
ians, birds, reptiles, sea squirts, and sea lampreys (38).
miR-155 and miR-361 are directly repressed by BCL-6, a 
transcriptional repressor required for germinal center formation. 
miR-361 is embedded in the CHM gene, which encodes a subunit 
of a Rab geranylgeranyl transferase and is known for its genetic 
inactivation in choroideremia (37). BCL-6 display a coordinated 
activity in sustaining high levels of AID expression in germinal 
center B cells undergoing CSR and SHM. By direct repressing 
miR-155 and miR-361, BCL-6 upregulates the expression of the 
target genes of these miRNAs, including AICDA and other ele-
ments involved in the maintenance of the germinal center B cell 
centroblast phenotype (37). The specific effect of miR-155 in the 
regulation of AID expression was demonstrated by the findings 
that disruption of the miR-155 binding site in the 3′ UTR of Aicda 
mRNA in B cells led to an increase in Aicda mRNA and AID protein 
by increasing the half-life of Aicda mRNA, resulting in increased 
CSR and c-Myc/IgH translocations (33, 34). Nevertheless, the role 
of miR-155 in regulating B cell function and antibody response 
is much more than modulating the expression of AID. miR-155 
is expressed at a high level in germinal center B cells and plays 
an important role in germinal center formation and subsequent 
antibody response following antigen challenge (30, 32, 39). miR-
155 deficiency in B cells resulted in reduced extra follicular and 
germinal center responses, decreased numbers of IgG1+ plasma 
cells and memory B cells, and failed production of high-affinity 
IgG1 antibodies (30). In B6/Faslpr/lpr mice, deficiency of miR-155 
results in a reduced autoantibody production and autoimmunity 
(40). This is likely stemmed from dysregulation of a variety of 
genes in multiple immune cells, including derepressed expression 
of SHIP-1 in B cells, which lead to mitigation of B-cell activation, 
proliferation and autoantibody production (40).
The 3′ UTR of Aicda mRNA contains multiple putative bind-
ing sites for miR-181b, which is predominantly expressed in lym-
phoid cells (10, 41). miR-181b is expressed at the highest levels 
in resting B cells and is downregulated upon B cell activation 
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by CSR-inducing stimuli (34, 42). Expression of miR-181b in B 
cells leads to down-regulation of AID at both the transcript and 
protein levels. It has been suggested that miR-181b and miR-155 
have non-overlapping functions in controlling AID expression. 
miR-181b may inhibit premature AID activity but allows proper 
AID transcriptional activation at early time points, while miR-
155 could narrow AID function at a later stage of activation (34). 
By controlling AID expression, miR-155 and miR-181b protect 
resting B cells and non-B cells from AID-mediated mutagenesis. 
Accordingly, in Burkitt’s lymphoma B cells, deficiency of miR-155 
expression is associated with high levels of somatic mutations and 
inter-chromosomal translocations (43).
ePiGeNeTiC ReGULATiON OF AiD 
TARGeTiNG iN CSR AND SHM
One fundamental question for B cell biology remains to be 
answered is how CSR and SHM machineries are targeted to the 
Ig locus. For CSR to take place, the IgH genes are subjected to 
transcriptional activation, RNA splicing, AID-mediated cytidine 
deamination, as well as DNA cleavage, repair, and recombina-
tion. Each of these events is likely associated with, and possibly 
regulated by specific changes in chromatin structure. Histone 
modifications in S and V(D)J regions are critical for targeting of 
the CSR and SHM machinery, respectively (Table 1). Chromatin 
structure that impacts on and likely regulate most aspects of gene 
expression, also contributes to the regulation of CSR and SHM. 
In B cells poised to undergo CSR, the IgH genes are in an “acces-
sible” chromatin conformation before CSR (44). Upon induction 
of germ-line transcription, histones H3 and H4 have been shown 
to be acetylated at the IH exon promoters and S regions (45, 46).
epigenetic Targeting of the CSR 
Machinery
Histone Modifications in CSR Targeting
Histone post-translational modifications are important for 
targeting of the CSR machinery to the upstream donor and the 
downstream acceptor S regions that are involved in CSR (Table 1). 
The significant levels of germline Iμ-Sμ-Cμ transcription and acti-
vating histone marks, such as H3K4me3, H3K36me3, H2BK5ac, 
H3K9ac/K14ac, H3K27ac, and H4K8ac, are observed in the 
donor Sμ region even in resting naïve B cells, suggesting that Sμ 
is in a constitutively open state and poised for switch recombina-
tion (8). CSR induction requires both primary and secondary 
(CSR-inducing) stimuli. Primary stimuli, such as engagement 
of B cell CD40 by CD154 expressed on activated T cells, and 
T-independent dual toll-like receptor (TLR) and BCR engage-
ment, induce B cell activation, proliferation, and differentiation. 
In conjunction with primary stimuli, secondary stimuli, which 
comprise cytokines (e.g., IL-4, TGF-β, and IFN-γ), direct class 
switching to IgG, IgA, or IgE by selecting the acceptor S region, 
through activation of S region histone modifications and induc-
ing specific germline IH-S-CH transcription (46–49). Primary 
stimuli induce histone-modifying enzymes and trigger chromatin 
decondensation in downstream S regions by removing repres-
sive H3K9me3 and H3K27me3. These allow histone-modifying 
enzymes to ride on the RNA Pol II to reach S regions during 
germline IH-S-CH transcription elongation (46, 47, 50–52). Upon 
RNA Pol II stalling, caused by complex secondary DNA structures, 
such as cruciform-like structures and R-loop, in S regions (2, 53), 
histone-modifying enzymes catalyze histone modifications in 
these regions. DNA transcription together with modified histones 
opens the chromatin in S regions, thereby allowing for access of 
CSR factors. The role of histone-modifying enzymes in CSR is 
further emphasized by the reduced S region histone modifications 
and CSR in B cells knockdown H3K4 methyltransferase Set1 (48), 
or H3K9 acetyltransferases Pcaf and Gcn5 (8).
In the donor and acceptor S regions, activating histone modi-
fications, such as H3K9ac and H3K4me3, are enriched at levels 
much higher than those in the associated IH promoter and CH 
regions (46, 47). These histone marks are read by CSR factors, 
including 14-3-3 adaptors, which, such as AID and histone-
modifying enzymes, are induced by primary CSR stimuli (54). 
14-3-3 adaptors directly interact with AID and target it to the 
upstream and downstream S regions that undergo recombina-
tion (2), thereby transducing the epigenetic code. 14-3-3 adaptors 
specifically bind to the combinatorial histone H3K9acS10ph 
modification in S regions and 5′-AGCT-3′ (2, 54) repeats. These 
are characteristic motifs of all IgH locus S regions, but not IH 
promoters, CH regions or other genome areas (54). Due to their 
high affinity for 5′-AGCT-3′ repeats, 14-3-3 can potentially bind 
all S regions. Nevertheless, these adaptors are recruited only to 
the S regions that undergo recombination (54). This is due to the 
open chromatin state of such regions as well as specific binding of 
14-3-3 to H3K9acS10ph (8). The specificity of 14-3-3 adaptors for 
H3K9acS10ph and 5′-AGCT-3′ repeats are evocative of RAG1/
RAG2 complex specificity for H3K4me3 and V, D and J gene 
recombination signal sequences (RSSs) (55).
H3K4 methylation, particularly H3K4me3, plays a critical 
role in AID-mediated DNA cleavage in S regions during CSR 
(48). The formation of H3K4me3 at AID target loci is depend-
ent on the histone chaperone complex, facilitates chromatin 
transcription (FACT), a chromatin-modifying complex during 
RNA processing (48, 56). We have shown that specific H3K4 
methyltransferases and H3K9 acetyltransferases can be induced 
by TLR or CD40 signaling and catalyze histone H3K4me3 and 
H3K9ac/K14ac modifications. These are decorated S regions, 
regardless of whether they are targets of CSR (8). Conversely, the 
combinatorial histone H3K9acS10ph modification specifically 
marks the S regions set to recombine and directly recruits 14-3-3 
adaptors for AID stabilization (8). 14-3-3 adaptors, which possess 
no enzymatic activity, function as histone code readers to recruit/
stabilize downstream effector molecules, which per se cannot read 
histone codes, consistent with the “histone code hypothesis” (57, 
58). Inhibition of the enzymatic activity of Gcn5/Pcaf histone 
acetyltransferases leads to decreased H3K9acS10ph, 14-3-3 
recruitment and AID stabilization in S regions, and CSR.
H3K9me3 is also present, although at a relatively low level, in 
Sμ but not downstream S regions. In the Sμ region, H3K9me3 
recruits the KAP1-HP1γ complex to stabilize AID (13). 
Accordingly, CSR to IgA can be impaired by deletion of the H3K9 
methyltransferase Suv39 (59). Histone modification readers that 
function as scaffolds, such as 14-3-3 adaptors, translesion DNA 
TABLe 1 | epigenetic marks/factors, and their functions in CSR and SHM.
Target(s) epigenetic mark(s) (Putative) functions Modulate Reference
CSR SHM
microRNAs
Aicda miR-93 Decrease expression of AID + + (9, 33–37)
miR-155
miR-181b
miR-361
lncRNAs
S regions Germline IH-S-CH transcripts Increase S region accessibility + − (2)
S regions Intronic switch RNA Recruit AID to S region + − (69)
S regions Antisense S region transcripts Increase S region accessibility + − (173)
VHDJH Antisense VHDJH transcripts Increase VHDJH region accessibility − + (173)
IgH 3′ RR 
super-enhancer
lncRNA-CSR Regulate IgH 3′ regulatory region super-enhancer function + − (70)
IgH and other AID 
target regions
xTSS-RNAs Recruit AID to ssDNA-forming site + + (67)
DNA MeTHYLATiON
V(D)J DNA hypomethylation Increases V(D)J region accessibility − + (84)
Igh 3′-LCR DNA hypomethylation Mediates germline VHDJH and IH-S-CH transcription + + (174)
HiSTONe MODiFiCATiONS
V(D)J H3K4me2/3, H3K9ac/K14ac, 
H4K8ac 
Increase V(D)J region accessibility and transcription − + (23, 72, 85)
iEμ H3K4me3, H3K9ac/K14ac Activate iEμ and enhance germline VDJ transcription and 
IH-S-CH transcription
+ + (46, 47)
Igh 3′-LCR H3K4me1/2 Mediate VDJ and germline transcription + + (175)
H3K9ac, H3K27ac, H4K8ac, 
H2BK5ac 
(47)
S region(s) H3K27me3 Decreases S region(s) accessibility + − (12)
H3K4me3, H3K9ac/K14ac, 
H3K27ac, H4K8ac
Increase S region(s) accessibility + − (12, 13, 45–49,  
61, 176)
H3K9me3 Recruits the HP1γ-KAP1 complex and AID to Sμ region + − (13)
H3K9acS10ph Recruits 14-3-3 adaptors and AID to S region(s) + − (8)
H4K20me2 Recruits 53BP1 to S region(s) in the DNA repair stage + − (62)
Aicda H3K4me3, H3K9ac/K14ac, 
H3K36me3
Increase transcription of Aicda + + (22, 47)
Repressive histone methylation: H3K9me3, H3K27me3.
Activating and recruiting histone modifications include histone acetylation: H3K9ac, H3K14ac, H3K27ac, H4K8ac, H2BK5ac, and H3K9ac; histone methylations: H3K4me2/3, 
H4K20me2, and H3K36me3; combinatorial histone H3K9acS10ph modification; histone phosphorylation: H2BS14ph; histone ubiquitination: H2AK119ub and H2BK120ub.
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synthesis polymerase Rev1 (60) and RPA (61), act as core for the 
assembly of macromolecular complexes on S region DNA, to 
stabilize AID and/or Ung for generation of DNA lesions. Histone 
modifications are also recognized by DNA repair factors, such as 
p53-binding protein 1 (53BP1), which may functions as a scaf-
fold to recruit/stabilize additional DNA repair factors for CSR. 
Abrogation of histone methyltransferase MMSET expression 
impairs H4K20me2 enrichment and 53BP1 recruitment in S 
regions, and results in reduced CSR (62).
Suppressor of Ty6 (Spt6), a RNA Pol II-interacting histone 
H3-H4 chaperone, also plays a role in the regulation of H3K4me3 
for SHM and CSR (23). Depletion of Spt6 impaired H3K4me3 
and AID-mediated DSBs in the S regions in CH12 B cells, which 
can otherwise be induced to express AID and CSR to IgA (23). 
In addition, knockdown Spt6 in human Burkitt’s lymphoma BL2 
cells overexpressing mutant AID (JP8Bdel) that lacks C-terminal 
16 aa residues, which are critical for CSR but not to SHM (63), 
abolished SHM and H3K4me3 in Ig VH region and non-Ig AID 
target genes (23). Thus, activating histone modifications are 
induced in S regions and create an open chromatin state, which 
allows for the access of the CSR machinery. Epigenetic specifica-
tion of CSR targeting entails reading of histone codes by scaffold 
proteins, which orchestrate the assembly of macromolecular 
complexes in the sequential DNA lesion and repair stages.
Long Non-Coding RNA and CSR Targeting
Long non-coding RNAs are evolutionarily conserved non-coding 
RNA molecules that are longer than 200  nt and located within 
the intergenic loci or regions overlapping antisense transcripts of 
protein coding genes (64–66). Their expression can be tissue- and 
cell-type specific. lncRNAs are involved in numerous cellular func-
tions, such as transcriptional regulation, RNA processing, RNA 
modification and epigenetic silencing. lncRNAs have been recently 
shown to play an important role in the targeting of the CSR machin-
ery (Table 1). They target AID to divergently transcribed loci in B 
cells (67). In B cells undergoing CSR, the RNA exosome, a cellular 
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RNA-processing/degradation complex is required for optimal 
CSR (68). The RNA exosome associates with AID, accumulates 
on S regions in an AID-dependent fashion. Both the cellular RNA 
exosome complex and a recombinant RNA exosome core complex 
inform robust transcription-dependent DNA deamination by AID 
in both strands of transcribed SHM substrates in vitro. In B cells, 
deficiency of Exosc3 or Exosc10, the essential subunits of the RNA 
exosome complex, impairs CSR and SHM (67, 69). Many novel 
RNA exosome substrate lncRNAs have been identified by tran-
scriptome analysis of Exosc3- or Exosc10-deficient B cells. RNA 
exosome-regulated, antisense-transcribed regions accumulate 
single-strand DNA structures containing RNA-DNA hybrids and 
recruit AID in B cell. RNA exosome regulation of lncRNA has been 
suggested to recruit AID to single-strand DNA-forming sites of 
antisense and divergent transcription in the B cell genome (67). In 
addition, a recent study has shown that an lncRNA generated by S 
region transcription followed by lariat debranching can fold into 
G-quadruplex structures, which can be directly bound by AID, 
thereby targeting of AID to S region DNA (70).
epigenetic Targeting of the 
SHM Machinery
Activation-induced cytidine deaminase initiates SHM by deami-
nating cytosine residues in Ig V(D)J genes. It also introduces 
DNA damages, including point-mutations, in non-Ig loci at a 
lower frequency. How AID is recruited to the target sites is not 
fully understood. AID has been suggested to target a specific 
microenvironment rather than a defined set of genes (71). The 
SHM machinery is targeted to the V(D)J region through unique 
targeting sequences, transcription, and possibly, DNA demeth-
ylation and histone modifications (Table 1) (72). Like CSR, SHM 
requires not only the expression of AID, but also transcription in 
the target regions. Alterations in chromatin structure at IgH may 
also play an important role in promoting and/or stabilizing AID 
targeting (73). AID targets a distinct set of hotspots, which are 
concentrated in genes that are highly transcribed but frequently 
stalled genes (74). AID associates with RNA Pol II (75). RNA Pol 
II transcription, as well as several chromatin alterations could 
facilitate the access of AID to Ig loci and give use to single-stranded 
DNA, a preferential substrate for AID deamination. However, 
transcription alone is insufficient to recruit AID activity (74). 
AID targets are predominantly grouped within topological com-
plex, highly transcribed superenhancers and regulatory clusters, 
which are enriched in chromatin modifications associated with 
active enhancers (such as H3K27Ac), they are also and marks of 
active transcription (such as H3K36me3), indicating that these 
features are universal mediators of AID recruitment (71, 74, 
76). In both human and mouse B cells, there is a strong overlap 
between hypermutated genes and superenhancer domains (71).
The phosphorylated histone H2B (H2BSer14P) correlates 
tightly with SHM and CSR. In Ig V(D)J and S regions, H2B phos-
phorylation requires AID and may be mediated by the histone 
kinase Mst1 (72, 77). It has been suggested that SHM and CSR trig-
ger distinct DNA damage responses and identify a novel histone 
modification pattern for SHM consisting of H2B (Ser14P) in the 
absence of γH2AX (72, 77). The non-Ig AID targets share important 
characteristics with Ig genes, namely, repetitive sequences that can 
form non-B DNA structures upon efficient transcription, and the 
accumulation of chromatin H3K4me3 histone marks (78).
The FACT complex may also promote SHM (56). FACT, 
a histone chaperone-type elongation factor, was originally 
discovered for its biochemical activity to promote transcription 
elongation of RNAPII on the nucleosomal DNA template (79). 
It has been suggested to remove nucleosomal histones and 
deposit them at the RNAPII of transcription site, and this allows 
the RNA polymerase to be proceed beyond the nucleosomes 
(80). FACT is important for inducing H3K4me3, which can 
be recognized by a protein complex with DNA cleaving activ-
ity and accumulates at SHM-targeted genomic regions (48). 
Furthermore, FACT and histone variant H3.3, a hallmark of 
replication-independent histone turnover, are enriched at the 
heavy and light chain V(D)J regions, the light chain Jκ5 region 
and the Sμ region 5′ flanking sequence (48). The importance 
of the chromatin histone-exchanging dynamics in SHM target 
regions, especially Ig genes, is emphasized by high abundant 
FACT and H3.3 deposition in the most efficient targets of SHM 
(56, 81). Histone post-translational modifications would also 
mediate recruitment of DNA repair factors, such as error-prone 
TLS DNA polymerases, in SHM at the DNA repair stage. 
H2AK119 ubiquitination (ub) and H2BK120ub are enriched 
in VHDJH but not CH regions and colocalize with DNA Pol η, 
an important TLS polymerase for SHM, in AID nuclear foci 
(82). Pol η is likely recruited to those loci by H2AK119ub and 
H2BK120ub, as well as by monoubiquitinated PCNA scaffold, 
through its ubiquitin-binding domain (83). As mentioned 
before, AID-dependent histone H2BSer14P mark in the V(D)J 
region (72) may also contributes to recruitment of DNA repair 
factors. The role of DNA hypomethylation in SHM has been 
suggested by the finding that only the hypomethylated allele 
is hypermutated in B cells carrying two nearly identical pre-
rearranged Igκ transgenic alleles, even though transcription of 
both alleles are comparable (84).
It is possible that DNA demethylation facilitates SHM targeting 
by promoting histone modifications H3K4me3, H3K9ac/K14ac 
and H4K8ac, which are enriched in the V(D)J region and associ-
ated with an open chromatin state (23, 72, 85). Both H3K4me3 
and H4K8ac are involved in SHM. Decreased H3K4me3 in VHDJH 
regions in human BL2 cells, a Burkitt’s lymphoma cell line that 
can be induced to undergo SHM, upon knockdown of histone 
chaperone Spt6 is associated with reduced VHDJH mutations 
(23). In BL2 cells, H4K8ac increases concomitantly with VHDJH 
mutations upon treatment with HDI trichostatin A (TSA) (85). 
Persistent H4K8ac in VλJλ region required E2A, whose inactiva-
tion result in decreased mutations (72, 86).
Some cis-acting regulatory regions, such as Ig enhancer and 
Ig enhancer-like sequences, are important for targeting SHM 
to Ig loci (87, 88). In chicken, mouse and human B cells that Ig 
locus enhancers and enhancer-like elements function as core 
diversification activator (DIVAC) sequences that work together 
to target SHM (88). In chicken DT40 B cells, short mammalian 
Igλ and IgH enhancer fragments can increase mutation rates by 
more than 20-fold (88). lncRNAs, which are likely to regulate 
many biological functions, have been recently shown to be link 
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to enhancer activity. lncRNAs are expressed in a lineage-specific 
fashion and function through RNA–protein, RNA–DNA, or 
RNA–RNA target interactions. They are induced to modulate 
innate and adaptive immunity (66). Many regulatory lncRNAs 
can be categorized as DNA accessibility modulators, and likely 
play a role in SHM targeting, especially in conjunction with the 
function of Ig enhancers (67). Thus, activating histone modifica-
tions, DNA hypomethylation, and possibly lncRNAs increase 
V(D)J region chromatin accessibility to the SHM machinery, 
including AID and error-prone DNA repair factors, which can 
be stabilized by modified histones.
ePiGeNeTiC ReGULATiON OF PLASMA 
CeLL DiFFeReNTiATiON
B cell differentiation is initiated by extracellular stimuli that bind 
to cellular receptors and trigger a signaling cascade resulting in the 
induction of transcription factors that reprogram B cells to secrete 
antibodies. The function of transcription factors is controlled by 
the accessibility to DNA through epigenetic modifications. Little 
is known about how the epigenetic mechanisms direct B cell dif-
ferentiation into antibody-secreting plasma cells (6). Plasma cells 
are terminally differentiated elements in the B cell lineage that 
mostly have undergone SHM and CSR. These cells do not prolifer-
ate, but secrete large volumes (107 molecules/h) of clone-specific 
antibodies. Plasma cells are derived from either germinal center 
or memory B cells. Although some memory B cells are IgM+, most 
memory B cells are class-switched and express mutated V(D)J 
gene segments. Upon reactivation by specific antigen, memory 
B cells differentiate into antibody-secreting plasma cells to medi-
ate an anamnestic humoral response (89). Reactivated memory 
B cells can also reenter into the germinal center reaction and 
undergo further CSR and/or SHM before differentiating into 
plasma cells or reverting back to memory B cells (90, 91).
Plasma cells display a transcriptional signature that is distinct 
from B cells (92). Their changes in gene expression correlated 
with the acquisition of permissive histone modifications, includ-
ing H3K4me1 and H3K4me4, which are enriched in active pro-
moters and distal enhancers and play an important role in B cell 
development (92, 93). Upregulation of Blimp-1, a transcriptional 
repressor, is central to plasma differentiation (6). Blimp-1 down-
regulates the expression of Bcl6, Pax5, and Spib, all of which inhibit 
B cell differentiation into plasma cells by binding to the promoters 
of these genes (6), and, possibly, deacetylating their promoters. 
Indeed, Pax5, Spib, and perhaps Bcl6 promoters display decreased 
histone acetylation in plasma cells (94, 95). Furthermore, Blimp-1 
can interact with HDACs that remove acetyl groups on a histone 
(94). In addition, in plasma cells, Blimp-1 down-regulates c-Myc 
expression through a similar epigenetic mechanism (94), thereby 
maintaining the terminal differentiation state of these cells (6). 
Finally, Blimp-1 can interact with H3K9 methyltransferase G9a 
and likely recruits this enzyme to the Pax5 and Spib promoters, 
thereby increasing H3K9me3 and repressing activation of these 
promoters (95, 96). Thus, epigenetic induction of Blimp-1 and 
Blimp-1-mediated epigenetic inhibition of target genes drives 
plasma cell differentiation, and possibly maintains plasma cell 
identity. Down-regulation of Pax-5 and Pax-5-driven Bcl-6 lead 
to derepression of the Prdm1 promoter from Bcl-6-mediated 
epigenetic silencing. This is associated with increased histone 
acetylation in the Prdm1 promoter, likely resulting from release 
of Bcl-6-bound HDACs (97, 98). Reduction of Blimp-1 in a 
plasmacytoid cell line by enforced expression of Bcl-6 resulted in 
re-expression of B cell markers, including CD19 (98).
Prdm1 mRNA contains a long (>2,000 nt) 3′ UTR, which can 
be potentially targeted by multiple miRNAs, including miR-9, 
miR-23b, miR-30, miR-125b, miR-127, and let-7 (10, 27, 28, 31, 
99–102). Overexpression of miR-125b in B cells impairs expres-
sion of Blimp-1 and inhibits B cell differentiation into plasma cells 
(31). In addition, miR-125b can downregulate IFN regulatory fac-
tor (Irf)-4, which reciprocally regulates Blimp-1 and is required 
for the generation of plasma cells (27, 31, 103). Furthermore, 
X-box binding protein (Xbp)-1 that governs late events of plasma 
cell differentiation can be downregulated by miR-127 (102).
ePiGeNeTiC ReGULATiON OF MeMORY 
B CeLL DiFFeReNTiATiON
B cell memory is a hallmark of adaptive immunity. Memory B 
cells are antigen-experienced quiescent B cells, which can be 
generated in response to both T-dependent antigens (usually 
proteins) and T-independent antigens (usually carbohydrates) 
(7). B cells quickly react to a second challenge with the same 
antigen, thereby providing humoral immune protection. While 
inherit epigenetic information from their active B cell precursors, 
memory B cells acquire new epigenetic marks, which make these 
resting B cells poised to quickly respond to experienced antigen. 
Expression of memory B cell hallmark genes, such as CD27 (in 
humans) and Cd38 (in mice), is likely mediated by histone modi-
fications induced during B cell activation (4). Genes that control 
B cell identity and function, including Pax5 and Spib, are also 
expressed in memory B cells, likely reflecting the epigenetic state 
that originated in naïve B cells and led them to memory B cells 
differentiation. Post-recombined S–S regions in the IgH locus 
show constitutive (upstream Sμ portion) or induced (downstream 
Sγ, Sϵ, or Sα portion) histone modifications, which could be 
transferred to memory B cells and result in comparable epigenetic 
landscapes in class-switched memory B cells (4). The functional 
distinction between memory B cells and their naïve counterparts 
could at least partially result from the epigenetic alterations.
Quiescent and activated B cells display different histone marks 
(104). In resting cells, histone lysine methylation was reduced as 
compared to activated cells (105). Enhancer of zeste homolog 2 
(Ezh2) catalyzes H3K27me3, which is enriched at transcription 
start sites of repressed genes, through its SET domain. EZH2 is 
highly expressed in human germinal center B cells. Inactivation 
of Ezh2 in mouse germinal center B cells resulted in a profound 
reduction of germinal center reactions, memory B cell formation, 
and antibody response (106). Ezh2 protected germinal center B 
cells against AID mutagenesis and facilitated cell cycle progres-
sion. Repression of Blimp-1 and Irf4 expression in germinal center 
B cells is also necessary to limit plasma cell differentiation (106). 
In Ezh2fl/flCγ1-Cre mice, the B cell differentiation stage-specific 
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Ezh2 deficiency resulted in profound impairment of germinal 
center reactions and memory B cell formation, suggesting that 
the methyltransferase activity of Ezh2 is essential for not only 
germinal center B cell functions but also generation of memory B 
cells (106). Furthermore, it has been recently shown that histone 
acetyltransferase monocytic leukemia zinc finger protein (MOZ), 
which specifically targets H3K9 and plays a role in stem cell self-
renewal, regulates B cell memory formation, controlling memory 
compartment composition (104). This activity of MOZ is B cell-
intrinsic and is required for establishing the germinal center gene 
expression program. B cell stage-specific deletion of MOZ alters 
fate decisions in both primary and secondary antibody responses. 
The lack of MOZ affected the functional outcome of antibody 
responses, with an increase in secondary germinal centers and 
a corresponding decrease in secondary high-affinity antibody-
secreting cell formation (104).
The differentiation of naïve B cells to germinal center B 
cells and then to plasma cells or memory B cells would also be 
associated with changes in DNA methylation. Several genes can 
be silenced by DNA methylation catalyzed by DNA methyltrans-
ferases (DNMTs), such as DNMT3a, which is highly expressed 
in memory B cells (107). In memory B cells, different expression, 
as compare to naïve B cells, of the immune activation related 
elements is likely concomitant with distinctive DNA methylation 
(108). This supports the concept that the memory B cell epig-
enome is poised to facilitate a more rapid and robust activation 
response than that of its naive counterparts.
As demonstrated by concomitant miRNA and mRNA profil-
ing, miRNAs play a regulatory role at every stage of the B cell 
peripheral differentiation process (28). Selected miRNAs, includ-
ing miR-125b and let-7, negatively regulate Prdm1 (10, 27, 28, 
101). Down-regulation of miR-15a and miR-16, which target 
Bcl2, likely contributes to memory B cell survival (27, 109) and 
re-expression of Krüppel-like factors (KLFs), which can bind 
HDACs, mediates memory B cell quiescence (110). miR-223 
is enriched in human memory B cells and down-regulates the 
expression of LMO2, a key transcription factor in B cell dif-
ferentiation (28). In addition to function as a negative regulator 
for CSR and SHM by silencing AID, miR-155 also plays an 
important role in memory B cell responses. miR-155 deficiency 
greatly reduced memory B cells (111). Several lncRNAs have 
been shown to be preferentially expressed in human memory B 
cells, but not in naïve B cells or B1 cells (112), suggesting that 
lncRNA also play a role in memory B cell differentiation. Thus, 
DNA methylation, histone modifications and non-coding RNAs, 
especially miRNAs, control gene expression programs that lead to 
B cell differentiation into plasma cells and memory B cells, and 
maintain the identity of these differentiated cells.
ePiGeNeTiC MODULATiON OF AiD AND 
Blimp-1 eXPReSSiON, CSR, SHM, AND 
PLASMA CeLL DiFFeReNTiATiON BY 
HDAC iNHiBiTORS
Histone deacetylases are a class of enzymes that remove the 
acetyl groups from the lysine residues on a histone leading to 
the formation of a condensed and transcriptionally silenced 
chromatin. HDIs block this action and can result in histone 
hyperacetylation, thereby affecting gene expression. HDIs have 
been shown to alter gene expression by altering chromatin acces-
sibility (113–115). In immune cells, these epigenetic modifiers 
exert modulatory effects even at moderate concentrations. By 
using well-characterized short-chain fatty acid (SCFA) HDIs, 
valproic acid (VPA) (116), and butyrate (117), we have shown 
that HDIs regulate intrinsic B cell functions that are critical in 
shaping effective antibody and autoantibody responses. Our 
findings were further supported by a recent publication show-
ing that HDIs Panobinostat (a novel broad-spectrum HDI) and 
Vorinostat (suberanilohydroxamic acid or SAHA) significantly 
impair antibody and autoantibody responses (118). VPA is an 
FDA-approved drug, widely used as an anticonvulsant and a 
mood-stabilizer. It selectively inhibits class I HDACs, particu-
larly, HDAC1 and HDAC2, and, less effectively, class IIa HDACs, 
of the four HDAC classes identified in mammals (116, 119). 
Butyrate is a major metabolite in the digestive tract, arising from 
bacterial fermentation of dietary fibers, mainly “resistant” starch 
(120, 121), and it is widely available as a dietary supplement. 
Butyrate modulates gene expression by selectively inhibiting 
HDAC1 and HDAC3, and, less effectively, other members of class 
I and class IIa HDACs (117). SCFA HDIs have been suggested to 
display significant selectivity for different HDACs (122). HDAC 
activity is mostly associated with multiprotein complexes, the 
role and composition of which are often cell type-specific. 
HDAC-associated proteins would specify the selectivity of HDI, 
which display different affinities for different HDAC/co-factor 
complexes. HDIs with diverse chemical properties target differ-
ent HDACs and HDAC/co-factor complexes, thereby regulating 
gene expression in a locus- and cell type-specific fashion (122). 
In B cells, HDIs would modulate miRNAs selectively, possibly 
as a result of HDACs existing in unique contexts of HDAC/
co-factor complexes, as occurring in these lymphocytes, par-
ticularly when in an activated state (10).
Although HDIs may also indirectly modulate antibody 
responses or diminish autoimmunity by affecting elements 
other than B cells, such as innate immune cells (123) and T 
cells (Treg, TH1, and TH17 cells), or inhibit proinflammatory 
cytokines (115, 124–126), HDIs would directly regulate B cell 
genes that are central to the peripheral differentiation of these 
lymphocytes and the maturation of antibody and autoantibody 
responses (Figure  2) (10). Silencing of AICDA/Aicda and 
PRDM1/Prdm1 (and XBP1/Xbp1) by HDIs has been found to be 
intrinsic to B cells and independent of other cellular elements, 
as shown by our in vitro experiments using purified human and 
mouse B cells, as well as our in vivo studies of the T-dependent 
response to NP-CGG and the T-independent response to 
NP-LPS. In both in  vivo and in  vitro, HDI-mediated down-
regulation of AICDA/Aicda and PRDM1/Prdm1 expression 
was associated with a concomitant increase of the respective B 
cell targeting miRNAs (miR-155, miR-181b, and miR-361 for 
AICDA/Aicda; miR-23b, miR-30a, and miR-125b for PRDM1/
Prdm1), in a tight dose-dependent fashion (10). HDI-induced 
down-regulation of XBP1/Xbp1 could be secondary to decreased 
Blimp-1 expression.
FiGURe 2 | Histone deacetylase inhibitors upregulate selected B cell miRNAs that silence AiD and Blimp-1 expression to epigenetically modulate 
CSR, SHM, plasma cell differentiation and antibody/autoantibody responses. HDAC inhibitors, including short-chain fatty acid butyrate and propionate 
produced by gut commensal bacteria through fermentation of dietary fiber, epigenetically modify CSR and SHM by upregulating miRNAs, which silence AICDA/
Aicda mRNA and PRDM1/Prdm1 mRNA. The upregulation of miRNA expression results from an increase in the histone acetylation of the host genes of these 
miRNAs. This leads to down-regulation of AID and Blimp-1 expression, and the dampening of CSR, SHM, and plasma cell differentiation.
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The selectivity of HDI-mediated silencing of AICDA/Aicda 
and PRDMI/Prdm1 in B cells that were induced to undergo CSR 
and plasma cell differentiation was demonstrated by genome-
wide mRNA-Seq and further emphasized by the unchanged 
expression of Ung, Irf4, HoxC4, Rev1, and Bcl6, as well as the 
unchanged expression of miR-19a/b, miR-20a, and miR-25, 
which are not known to regulate AICDA/Aicda or PRDMI/
Prdm1 (10, 99). This, however, cannot rule out the possibility 
that HDI regulated other B cell factors (e.g., NF-κB, Id2/3, or 
Pax5), which contributed to the reduction of AID or Blimp-1. 
Nevertheless, relief of the HDI-mediated repression of luciferase 
activity under the control of Aicda and Prdm1 mRNA 3′ UTRs 
bearing mutated miR-155, miR-181b, miR-23b, miR-30a, and 
miR-125b target sites demonstrated that miRNAs are indeed 
direct effectors of the HDI-mediated repression of such 
selected genes in B cells (10).
Potential Role for Gut Microbiota-
Derived Short-Chain Fatty Acid HDAC 
inhibitors in the Modulation of Antibody 
Response
At ant time, the human body carries 1013–1014 microorgan-
isms, a number 10-fold more than the total number of human 
cells in the body. Human gastrointestinal tract microbiota 
composed of up to 1,000–1,150 bacterial species, which play 
an important role in nutritional, metabolic and physiological 
processes that are crucial for the maintenance of human health. 
Gut commensal bacteria are critical regulators of health and 
disease by protecting against pathogen while also maintaining 
immune tolerance to allergens (127–131). Commensal bacteria 
may modulate host immunity through metabolite-dependent 
mechanisms (129, 131). SCFAs, such as acetic acid, propionic 
FiGURe 3 | Dysregulation of AiD result in autoantibody-mediated autoimmunity, ige-mediated allergic response and tumoral genesis. AID initiates 
CSR and SHM by deaminating dCs into dUs yielding dU:dG mismatches, which lead to point-mutations in Ig V(D)J regions and DSBs in S regions. Aberrant AID 
expression result from epigenetic dysregulation can lead to a dysregulated antibody/autoantibody response and AID-mediated DNA mutagenesis, which can cause 
autoimmunity, allergic response, or tumoral genesis.
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acid, and butyric acid, which are generated in the colon by 
commensal bacteria through digestion of dietary fiber, are 
among the most abundant of these dietary metabolites. They 
are important for gut motility and colonocyte development. 
SCFAs function through binding to host cell surface receptors, 
such as GPR41, GPR43, and GPR109A, and through their HDI 
activity (132). It has been suggested that SCFAs produced in the 
gut could distribute systemically and shape the immunological 
environment in the respiratory system, thereby influencing the 
severity of allergic inflammation (132).
Mice fed a low-fiber diet displayed decreased serum levels 
of SCFAs and increased IgE-mediated allergic inflammation in 
the lung, while a high-fiber diet increased levels of SCFAs and 
were protected against allergic airway disease (132). Butyrate 
and propionate, which are potent HDIs, modulate the function 
of intestinal macrophages and naive T cells to promote epige-
netic changes that regulate the expression of genes responsible 
for differentiation into regulatory T cells and IL-10-producing 
T cells (121, 132, 133). Our recent findings that butyrate modu-
lates AID expression and CSR to IgG, IgA, and IgE, as well as 
plasma cell differentiation through its direct HDI activity on B 
cells (10), indicates that this SCFA can play an important role 
in modulating antibody responses of gut lymphoid organs. A 
diverse microbial population, which would produce an appro-
priate amount of SCFA HDIs, particularly, butyrate, is required 
to maintain a baseline immune-regulatory state, including IgG, 
IgA, and IgE levels. Elevated serum IgE and CSR to IgE in B 
cells at mucosal sites in the absence of microbial colonization in 
germ-free mice and in mice with low-diversity gut microbiota 
(134) further emphasize the important role for gut commensal 
bacteria-produced butyrate in modulating IgE production. 
Altered composition and decreased bacterial diversity of gut 
microbiota would lead to changes in absolute and relative levels 
of SCFA HDIs and, therefore, changes in systemic IgG, IgA 
and IgE levels and specificities, which contribute to altered 
immunity and increased susceptibility to immune-mediated 
diseases.
B CeLL ePiGeNeTiC DYSReGULATiON iN 
AUTOiMMUNiTY AND 
LYMPHOMAGeNeSiS
Epigenetic factors also play an important role in the pathogenesis 
of B cell-related immune disorders, such as autoimmunity, aller-
gic states and B cell malignancies, by integrating the effects of 
genetic makeup and the environment, two major disease-causing 
factors. Epigenetic dysregulation would compound genetic 
susceptibility in the generation of autoantibodies and autoim-
munity, as suggested by alterations of histone modifications and 
DNA methylation in patients with lupus, autoimmunity in mice 
with miRNA dysregulation (9), and low penetrance (25–45%) of 
lupus in monozygotic twins (135). The development of allergic 
diseases has been associated with environmental conditions, 
such as diet, drugs, toxins, sex hormones, and microbiota, all of 
which can impact the epigenetic profile (136, 137). Aberrant AID 
expression that can result from epigenetic dysregulation can lead 
to autoantibody-mediated autoimmunity, IgE-mediated allergic 
responses and tumorigenesis (Figure 3).
epigenetic Changes and Autoimmunity
Systemic autoimmune diseases, such as SLE, rheumatoid 
arthritis, systemic sclerosis, and dermatomyositis, are associated 
with overall DNA hypomethylation (1, 138, 139). Autoreactive 
TABLe 2 | B cell epigenetic dysregulation and lymphomagenesis.
Neoplasm epigenetic change Potential impacts of 
epigenetic changes
Reference
DLBCL,  
FL
Loss-of-function 
mutation of HAT 
genes CREBBP  
and EP300
Reduce P53 and BCL6 
acetylation
(177, 178)
HD, NHL Deregulation 
of the H3K27 
methyltransferase 
EZH2
Malignant GC B cell 
transformation
(179)
Multiple 
myeloma
Overexpression 
of H3K36 
methyltransferase 
MMSET/NSD2
Alter H3K36 and H3K27 
methylation, upregulate 
c-MYC expression by 
reducing c-MYC targeting 
miR-126
(180)
NHL, 
DLBCL, 
FL, MLL
Dysregulation 
of the H3K4 
methyltransferase 
MLL2/MLL3/KMT2D
Modulate cell-type- 
and stage-specific 
transcriptional programs 
by regulating chromatin 
accessibility at enhancer 
regulatory sequences
(181)
NHL, 
DLBCL
Aberrant DNA 
methylation
Promote aberrant gene 
expression
(155, 182, 
183)
B cell CLL miR-15a/16-1 
depletion
Aberrant expression of cell 
cycle regulators Ccnd2, 
Ccnd3, Cdk4, Cdk6 and 
Chk1, and anti-apoptotic 
protein BCL2
(171, 184)
NHL,  
HD, BL
miR-155 deregulation Enhance/sustain AID 
mutagenic activity
(37, 185)
DLBCL, 
BL
Overexpression of the 
miR-17-92 cluster
Downregulate inhibitors 
of the PI3K (Pten), NF-κB 
(A20, Cyld) and the intrinsic 
apoptotic (Bim) pathways; 
alter MYC-centered 
regulatory network
(151, 186, 
187)
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B cells in lupus patients are characterized by lack of ability to 
induce DNA methylation that extends their survival (140). In 
mice, prolonged treatment with DNA methylation inhibitors, 
or adaptive transfer of B cells treated with DNMT inhibitors, 
resulted in autoantibody production and lupus-like disease (141, 
142). The role of DNA methylation in autoimmune diseases is 
further emphasized by the discordance of SLE in monozygotic 
twins. B cells isolated from SLE patients displayed profound 
defects in DNA methylation, as compared to those from healthy 
monozygotic siblings (135). The decreased DNA methylation 
in autoreactive B cells likely resulted from reduced DNMT1 
and DNMT3b expression; it could also result from active DNA 
demethylation mediated by AID-mediated cytosine deamination 
(143). Indeed, AID is upregulated in B cells of lupus patients or 
lupus-prone mice (3, 9, 144). The contribution of aberrant histone 
modifications to lupus development has been strongly suggested 
by the increased histone acetylation and reduced autoantibody 
production in lupus-prone mice treated with HDIs (1, 10, 145).
Dysregulation of miRNAs has been associated with autoim-
minty. miRNAs are aberrantly expressed in different cell types 
and tissues in patients with autoimmune disease. B cell-specific 
deletion of Dicer, which is critical for miRNA maturation, resulted 
in a distorted BCR repertoire with increased of autoreactivity, 
suggesting a role for miRNAs in preventing the generation of self-
reactive antibodies (9, 146, 147). In lupus-prone MRL/Faslpr/lpr mice, 
miR-150 is downregulated in spleen B cells, as compared to that in 
MRL/Fas+/+ mice (148), possibly as a result of decreased acetylation 
and transcription of the miR-150 host gene due to defective HDAC 
activity. Indeed, specific knock-in dominant negative mutant of 
histone acetyltransferase p300 in B cells resulted in production 
of class-switched anti-double-stranded DNA autoantibodies 
and development of lupus-like symptoms (149). Conversely, 
elevated expression of some miRNAs can also contribute to the 
development of autoimmunity. In lupus mice, expression miR-21 
is upregulated in B cells, silencing of this miRNA ameliorates 
autoimmune splenomegaly (150). Constitutively expression of 
miR-17 ~ 92 in transgenic mice results in an increased numbers of 
germinal center B cells in the spleen and peripheral lymph nodes 
that may lead to autoimmune response (151).
epigenetics Changes and 
Lymphomagenesis
At all stages of cancer development, inappropriate epigenetic 
marks interact with genetic alterations to promote neoplastic 
transformation and tumor cell progression (152, 153). The epig-
enome of B cell lymphomas is characterized by global changes in 
DNA methylation and histone modification patterns, which var-
ies with chromosomal regions, local gene density, as well as DNA 
and histone modification status of neighboring genes (Table 2) 
(154, 155). Aberrant DNA hypomethylation of promoters can 
lead to increased transcription of genes with oncogenic potential, 
and aberrant DNA hypermethylation can lead to decreased tran-
scription of genes with tumor suppressor function. For example, 
mantle B cell lymphomas display DNA hypomethylation in 
promoters of genes that are involved in pathways controlling cell 
cycle or apoptosis, such as Cdk5, and aberrant hypermethylation 
in the promoter of tumor suppressor genes, such as Cdkn2b 
(156). Hypermethylation is likely associated with increased 
expression of DNMTs, such as DNMT3b, which is upregulated 
in diffuse lager B cell lymphomas (157). Accordingly, Dnmt3b 
transgenic mice develop mediastinal B cell lymphomas, which 
display significantly altered methylation patterns (157). Aberrant 
hypomethylation could involve AID, which can mediate active 
DNA demethylation (158) and is upregulated in human B cell 
non-Hodgkin lymphomas (NHL) (159).
Active DNA demethylation can also be initiated by the 10–11 
translocation (Tet) family of proteins Tet1, Tet2, and Tet3, which 
catalyze the oxidation of 5mC to 5-hydroxymethylcytosine 
(5hmC), a critical step for ultimate removal of a methyl mark (160, 
161). Reduced expression of Tet proteins that lead to decreased 
5hmC has been shown to associate with tumor development, 
suggests an important role of Tet proteins and 5hmC in normal 
cellular function (162). Tet1 is required for maintaining the 
normal abundance and distribution of 5hmC, which prevented 
hypermethylation of DNA in B cells (163). It is important for 
regulation of the B cell lineage and of genes encoding molecules 
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involved in chromosome maintenance and DNA repair. Tet1 may 
function as a tumor suppressor of B cell malignancy. Deletion of 
Tet1 in mice promotes the development of B cell lymphoma (163).
Altered expression or mutation of the histone-modifying 
enzymes promotes aberrant gene expression, which is respon-
sible for many tumor changes (164). Aberrant germinal center 
development is common in many B cell malignancies. EZH2, a 
histone methyltransferase component of polycomb repression 
complex (PRC)2 that catalyzes H3K27me3 and promotes tumor 
growth, is highly expressed in germinal center B cells and is often 
constitutively activated in germinal center-derive NHLs. EZH2 
prevents apoptosis caused by DNA damage, including that gener-
ated by AID, facilitated cell cycle progression, and silenced Blimp-
1, which can function as tumor suppressor (106). Inhibition of 
EZH2 in NHL cells induces Blimp-1, which impairs tumor growth. 
Overexpression of EZH2 is associated with B lymphomagenesis 
(165). Somatic mutations at Y641 and A677 residues within the 
catalytic domain of EZH2 have been found in diffuse large B 
cell lymphoma and follicular lymphoma (166). These mutations 
promote EZH2 activity and increase H3K27me3 levels in those 
cells (165). Furthermore, other histone-modifying enzymes, such 
as histone acetyltransferases CBP and p300, histone methyltrans-
ferases MLL2, and histone demethylases UTX and JMJD2C, are 
frequently mutated in B cell lymphomas (157). Mutations in these 
enzymes are likely mediated by AID, which is highly expressed in 
those neoplastic B cells, and result in aberrant patterns of histone 
modifications and disruption of chromatin structure, ultimately 
leading to dysregulated gene transcription programs.
Dysregulated miRNA expression also contributes to B lympho-
magenesis (28, 167). The miR-17 ~ 92 cluster, which consists of six 
miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and 
miR-92-1) that target the tumor repressor genes Bim and Pten, is 
often increased in human lymphomas (151, 168). Accordingly, 
ectopic expression of the miR-17  ~  92 cluster in lymphocytes 
leads to development of lymphoproliferative disease (151, 168). 
Conversely, expression of miR-15 and miR-16-1, which target 
anti-apoptotic oncogene Bcl-2, is downregulated in chronic 
lymphocytic leukemia B cells (169, 170). Knockout miR-15a and 
miR-16-1 in B cells results in clonal lymphoproliferative disorders 
(171). B cell lymphomas often express significant amounts of 
mRNA isoforms with shorter 3′ UTRs, which lack miRNA-bind-
ing sites, thereby escaping miRNA-directed silencing (172). For 
example, a short Cyclin D1 mRNA isoform that lacks part of the 
3′ UTR is expressed in a subset of mantle cell lymphomas (172). 
These cells have increased expression of Cyclin D1, an important 
regulator of cell cycle progression, and B cell proliferation. Thus, 
by allowing selected oncogenes to escape regulation by their 
modulatory miRNAs, the shortening of 3′ UTRs may provide an 
important mechanism in B cell neoplastic transformation.
CONCLUDiNG ReMARKS
Epigenetic changes are critical in shaping B cell differentiation 
functions, such as CSR, SHM, generation of plasma cells as well 
as memory B cells, for the production of class-switched and 
high affinity antibodies. In addition, a growing body of evidence 
implicates the involvement of epigenetic mechanisms in immune 
programing and development of allergic and autoimmune dis-
eases. Nevertheless, important questions on the nature and role of 
such epigenetic changes remain to be answered. These include the 
mechanisms by which histone posttranslational modifications 
and non-coding RNAs target the CSR and SHM machineries, 
particularly the selective recruitment of AID, to the Ig locus and 
how the dynamics of these epigenetic modifications orchestrate 
AID-mediated DNA lesion and DNA repair processes. High-
affinity antibodies are generated in germinal centers through 
SHM and selection of higher affinity B cell submutants for survival 
and expansion. These B cells will then undergo differentiation to 
plasma cells or memory B cells. Much needs be understood on 
the role of epigenetic modifications in the selection of germinal 
center B cells and in what determines whether a germinal B 
cell becomes a memory B cell or a plasma cell. These processes 
would involve unique epigenetic and transcriptional changes. 
Furthermore, altered DNA methylation, histone methylation 
and acetylation, and miRNA expression, resulting in immune 
imbalance, have been shown to be associated with the onset and 
progression of allergic and autoimmune diseases, as well as B cell 
lymphomagenesis. Thus, knowledge of the epigenetic profiles 
associated with B cell development and peripheral differentiation, 
and molecular mechanisms that cause and result from disease-
associated epigenetic patterns in B cells is required to understand 
the pathophysiology of allergic and autoimmune diseases, as well 
as B cell malignancies.
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